Listeria monocytogenes and its products as agents for cancer immunotherapy

Advances in Immunology

Volumn 113, Issue , 2012, Pages 81-118

  Guirnalda, Patrick ^a   Wood, Laurence ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer vaccines; Listeria monocytogenes; Tumor antigens; Tumor immunotherapy; Tumor vasculature

Indexed keywords

ALPHA ACTIN; BACTERIAL VECTOR; CANCER VACCINE; CARRIER PROTEIN; COMPLEMENTARY DNA; ENDOGLIN; IMMUNOLOGICAL ADJUVANT; LISTERIOLYSIN O; MESSENGER RNA; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; NUCLEOPROTEIN; PROTEIN E7; TUMOR ANTIGEN; VIRULENCE FACTOR;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BACTERIAL CLEARANCE; BACTERIOLOGY; BREAST CANCER; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL EFFECTIVENESS; COLON CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; FIBROSARCOMA; FOLLICULAR LYMPHOMA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; KIDNEY CANCER; LISTERIA MONOCYTOGENES; LISTERIOSIS; LUNG METASTASIS; MELANOMA; NONHUMAN; PLEIOTROPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

EID: 84855905938     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394590-7.00004-X     Document Type: Chapter

References (122)

1. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., von Boehmer H., Bronson R., Dierich A., Benoist C., Mathis D. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-1401.
2. Anderson M.S., Venanzi E.S., Chen Z., Berzins S.P., Benoist C., Mathis D. The cellular mechanism of Aire control of T cell tolerance. Immunity 2005, 23:227-239.
3. Bahey-El-Din M., Casey P.G., Griffin B.T., Gahan C.G. Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors. J. Med. Microbiol. 2010, 59:904-912.
4. Beatty G.L., Paterson Y. Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol. Res. 2001, 24:201-210.
5. Biron C.A., Gazzinelli R.T. Effects of IL-12 on immune responses to microbial infections, a key mediator in regulating disease outcome. Curr. Opin. Immunol. 1995, 7:485-496.
6. Brockstedt D.G., Giedlin M.A., Leong M.L., Bahjat K.S., Gao Y., Luckett W., Liu W., Cook D.N., Portnoy D.A., Dubensky T.W. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl. Acad. Sci. USA 2004, 101:13832-13837.
7. Bruhn K.W., Craft N., Nguyen B.D., Yip J., Miller J.F. Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2. Vaccine 2005, 23:4263-4272.
8. Brzoza K.L., Rockel A.B., Hiltbold E.M. Cytoplasmic entry of Listeria monocytogenes enhances dendritic cell maturation and T cell differentiation and function. J. Immunol. 2004, 173:2641-2651.
9. Burrows F.J., Derbyshire E.J., Tazzari P.L., Amlot P., Gazdar A.F., King S.W., Letarte M., Vitetta E.S., Thorpe P.E. Up-regulation of endoglin on vascular endothelial cells in human solid tumors, implications for diagnosis and therapy. Clin. Cancer Res. 1995, 1:1623-1634.
10. Campbell M.J., Esserman L., Byars N.E., Allison A.C., Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 1990, 145:1029-1036.
11. Campoli M.R., Chang C.C., Kageshita T., Wang X., McCarthy J.B., Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA), a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol. 2004, 24:267-296.
12. Cha S.C., Kwak L.W., Ruffini P.A., Qin H., Neelapu S., Biragyn A. Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. J. Immunol. Methods 2006, 312:79-93.
13. Chang H.L., Gillett N., Figari I., Lopez A.R., Palladino M.A., Derynck R. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res. 1993, 53:4391-4398.
14. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas, with a report of ten original cases. Am. J. Med. Sci. 1893, 105:487-511.
15. Coley W.B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus of erysipelas and the bacillus prodigiosus). Practitioner 1909, 83:589-613.
16. D'Andrea A., Rengaraju M., Valiante N.M., Chehimi J., Kubin M., Aste M., Chan S.H., Kobayashi M., Young D., Nickbarg E. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med. 1992, 176:1387-1398.
17. Decatur A.L., Portnoy D.A. A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 2000, 290:992-995.
18. Derbinski J., Schulte A., Kyewski B., Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2001, 2:1032-1039.
19. Dietrich G., Bubert A., Gentschev I., Sokolovic Z., Simm A., Catic A., Kaufmann S.H., Hess J., Szalay A.A., Goebel W. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol. 1998, 16:181-185.
20. Dominiecki M.E., Beatty G.L., Pan Z.K., Neeson P., Paterson Y. Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol. Immunother. 2005, 54:477-488.
21. Drake C.G., Jaffee E., Pardoll D.M. Mechanisms of immune evasion by tumors. Adv. Immunol. 2006, 90:51-81.
22. Düwel A., Eleno N., Jerkic M., Arevalo M., Bolaños J.P., Bernabeu C., López-Novoa J.M. Reduced tumor growth and angiogenesis in endoglin-haploinsufficient mice. Tumour Biol. 2007, 28:1-8.
23. Ercolini A.M., Machiels J.P., Chen Y.C., Slansky J.E., Giedlen M., Reilly R.T., Jaffee E.M. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 2003, 170:4273-4280.
24. Folkman J. Tumor angiogenesis, therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
25. Folkman J. Tumor angiogenesis and tissue factor. Nat. Med. 1996, 2:167-168.
26. Galan J.E., Levine M.M. Can a "flawless" live vector vaccine strain be engineered?. Trends Microbiol. 2001, 9:372-376.
27. Gallegos A.M., Bevan M.J. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J. Exp. Med. 2004, 200:1039-1049.
28. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., Shah K.V., Sidransky D. Evidence for a causal association between human papilloma virus and a subset of head and neck cancers. J. Natl. Cancer Inst. 2000, 92:709-720.
29. Gunn G.R., Zubair A., Peters C., Pan Z.K., Wu T.C., Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 2001, 167:6471-6479.
30. Hartmann G., Krieg A.M. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999, 6:893-903.
31. Hu J.K., Kagari T., Clingan J.M., Matloubian M. Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation. Proc. Natl. Acad. Sci. USA 2001, 108:E118-E127.
32. Huang B., Zhao J., Shen S., Li H., He K.L., Shen G.X., Mayer L., Unkeless J., Li D., Yuan Y., Zhang G.M., Xiong H., et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007, 67:4346-4352.
33. Hussain S.F., Paterson Y. CD4+CD25+ regulatory T cells that secrete TGF-beta and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 2004, 27:339-346.
34. Hussain S.F., Paterson Y. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol. Immunother. 2005, 54:577-586.
35. Ikonomidis G., Paterson Y., Kos F.J., Portnoy D.A. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J. Exp. Med. 1994, 180:2209-2218.
36. Ishizaki H., Song G.Y., Srivastava T., Carroll K.D., Shahabi V., Manuel E.R., Diamond D.J., Ellenhorn J.D. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J. Immunother. 2010, 33:609-617.
37. Jensen E.R., Selvakumar R., Shen H., Ahmed R., Wettstein F.O., Miller J.F. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J. Virol. 1997, 71:8467-8474.
38. Kaminski M.S., Kitamura K., Maloney D.G., Campbell M.J., Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 1986, 136:1123-1130.
39. Kim S.H., Castro F., Gonzalez D., Maciag P.C., Paterson Y., Gravekamp C. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br. J. Cancer 2008, 99:741-749.
40. Kim S.H., Castro F., Paterson Y., Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009, 69:5860-5866.
41. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 1996, 93:2879-2883.
42. Kolb-Mäurer A., Gentschev I., Fries H.W., Fiedler F., Bröcker E.B., Kämpgen E., Goebel W. Listeria monocytogenes-infected human dendritic cells, uptake and host cell response. Infect. Immun. 2000, 68:3680-3688.
43. Kowalski P.J., Rubin M.A., Kleer R. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Cancer Res. 2003, 5:R217-R222.
44. Kwak L.W., Campbell M.J., Zelenetz A.D., Levy R. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma, active immunization with tumor-derived idiotypic immunoglobulin. Blood 1990, 76:2411-2417.
45. + T cell responses that home to the tumor site. J. Virol. 2001, 75:9654-9664.
46. Lancellotti M., Brocchi M., da Silveira W.D. Bacteria-induced apoptosis, an approach to bacterial pathogenesis. Braz. J. Morphol. Sci. 2006, 23:75-86.
47. Lee S.H., Mizutani N., Mizutani M., Luo Y., Zhou H., Kaplan C., Kim S.W., Xiang R., Reisfeld R.A. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol. Immunother. 2006, 55:1565-1574.
48. Leong M.L., Hampl J., Liu W., Mathur S., Bahjat K.S., Luckett W., Dubensky T.W., Brockstedt D.G. Impact of preexisting vector-specific immunity on vaccine potency, characterization of Listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice. Infect. Immun. 2009, 77:3958-3968.
49. Li C., Guo B., Wilson P.B., Stewart A., Byrne G., Bundred N., Kumar S. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int. J. Cancer 2000, 89:122-126.
50. Liau L.M., Jensen E.R., Kremen T.J., Odesa S.K., Sykes S.N., Soung M.C., Miller J.F., Bronstein J.M. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 2002, 62:2287-2293.
51. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August T.J., Pardoll D.M., Wu T.C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996, 56:21-26.
52. Lin C.W., Lee J.Y., Tsao Y.P., Shen C.P., Lai H.C., Chen S.L. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int. J. Cancer 2002, 102:629-637.
53. Liston A., Lesage S., Wilson J., Peltonen L., Goodnow C.C. Aire regulates negative selection of organ-specific T cells. Nat. Immunol. 2003, 4:350-354.
54. Liston A., Gray D.H., Lesage S., Fletcher A.L., Wilson J., Webster K.E., Scott H.S., Boyd R.L., Peltonen L., Goodnow C.C. Gene dosage-limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J. Exp. Med. 2004, 200:1015-1026.
55. Loeffler D.I., Schoen C.U., Goebel W., Pilgrim S. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Infect. Immun. 2006, 74:3946-3957.
56. Lowy D.R., Kirnbauer R., Schiller J.T. Genital human papillomavirus infection. Proc. Natl. Acad. Sci. USA 1994, 91:2436-2440.
57. Luo Y., Markowitz D., Xiang R., Zhou H., Reisfeld R.A. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Vaccine 2007, 25:1409-1415.
58. Maciag P.C., Seavey M.M., Pan Z.K., Ferrone S., Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008, 68:8066-8075.
59. Maciag P.C., Radulovic S., Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine, a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009, 27:3975-3983.
60. Maloney D.G., Brown S., Czerwinski D.K., Liles T.M., Hart S.M., Miller R.A., Levy R. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma, the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992, 80:1502-1510.
61. Marcus R., Imrie K., Belch A., Cunningham D., Flores E., Catalano J., Solal-Celigny P., Offner F., Walewski J., Raposo J., Jack A., Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
62. McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 2006, 26:154-158.
63. Moore D.H., Tian C., Monk B.J., Long H.J., Omura G.A., Bloss J.D. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma, a Gynecologic Oncology Group Study. Gynecol. Oncol. 2010, 116:44-49.
64. Mustafa W., Maciag P.C., Pan Z.K., Weaver J.R., Xiao Y., Isaacs S.N., Paterson Y. Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol. 2009, 22:195-204.
65. Niethammer A.G., Xiang R., Becker J.C., Wodrich H., Pertl U., Karsten G., Eliceiri B.P., Reisfeld R.A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 2002, 8:1369-1375.
66. Nitcheu-Tefit J., Dai M.S., Critchley-Thorne R.J., Ramirez-Jimenez F., Xu M., Conchon S., Ferry N., Stauss H.J., Vassaux G. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J. Immunol. 2007, 179:1532-1541.
67. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59:3128-3133.
68. Paglia P., Arioli I., Frahm N., Chakraborty T., Colombo M.P., Guzmàn C.A. The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. Eur. J. Immunol. 1997, 27:1570-1575.
69. Pamer E.G., Sijts A.J., Villanueva M.S., Busch D.H., Vijh S. MHC class I antigen processing of Listeria monocytogenes proteins, implications for dominant and subdominant CTL responses. Immunol. Rev. 1997, 158:129-136.
70. Pan Z.K., Ikonomidis G., Lazenby A., Pardoll D., Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1995, 1:471-477.
71. Pan Z.K., Ikonomidis G., Pardoll D., Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 1995, 55:4776-4779.
72. Pan Z.K., Weiskirch L.M., Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 1999, 59:5264-5269.
73. Paterson Y., Guirnalda P.D., Wood L.M. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin. Immunol. 2010, 22:183-189.
74. Peng X., Hussain S.F., Paterson Y. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function. J. Immunol. 2004, 172:6030-6038.
75. Peng X., Treml J., Paterson Y. Adjuvant properties of listeriolysin O protein in a DNA vaccine strategy. Cancer Immunol. Immunother. 2007, 56:797-806.
76. Perez-Gomez E., Villa-Morales M., Santos J., Fernandez-Piqueras J., Gamallo C., Dotor J., Bernabeau C., Quintanilla M. A role for endoglin as a suppressor of malignancy during mouse skin carcinogenesis. Cancer Res. 2007, 67:10268-10277.
77. Peters C., Paterson Y. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine 2003, 21:1187-1194.
78. Piccirillo C.A., Shevach E.M. Cutting edge: Control of CD8(+) T cell activation by CD4(+)CD25(+) immunoregulatory cells. J. Immunol. 2001, 167:1137-1140.
79. Radford K.J., Higgins D.E., Pasquini S., Cheadle E.J., Carta L., Jackson A.M., Lemoine N.R., Vassaux G. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: Application to cancer immunotherapy. Gene Ther. 2002, 9:1455-1463.
80. Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 2000, 192:295-302.
81. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
82. Schafer R., Portnoy D.A., Brassell S.A., Paterson Y. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J. Immunol. 1992, 149:53-59.
83. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
84. Schnupf P., Hofmann J., Norseen J., Glomski I.J., Schwartzstein H., Decatur A.L. Regulated translation of listeriolysin O controls virulence of Listeria monocytogenes. Mol. Microbiol. 2006, 61:999-1012.
85. Schoen C., Loeffler D.I., Frentzen A., Pilgrim S., Goebel W., Stritzker J. Listeria monocytogenes as novel carrier system for the development of live vaccines. Int. J. Med. Microbiol. 2008, 298:45-58.
86. Seavey M.M., Paterson Y. Anti-angiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in tumor immunoediting. Breast Cancer 2009, 1:19-30.
87. Seavey M.M., Verch T., Paterson Y. Anticancer vaccine strategies. Handbook of Listeria monocytogenes 2008, 481-511. CRC Press, USA. D. Liu (Ed.).
88. Seavey M.M., Pan Z.K., Maciag P.C., Wallecha A., Rivera S., Paterson Y., Shahabi V. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin. Cancer Res. 2009, 15:924-932.
89. Seavey M.M., Pan Z.K., Maciag P.C., Wallecha A., Rivera S., Paterson Y., Shahabi V. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J. Immunol. 2009, 182:5537-5546.
90. Seedorf K., Oltersdorf T., Krämmer G., Röwekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J. 1987, 6:139-144.
91. Sewell D.A., Douven D., Pan Z.K., Rodriguez A., Paterson Y. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch. Otolaryngol. Head Neck Surg. 2004, 130:92-97.
92. Sewell D.A., Shahabi V., Gunn G.R., Pan Z.K., Dominiecki M.E., Paterson Y. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res. 2004, 64:8821-8825.
93. Sewell D.A., Pan Z.K., Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008, 26:5315-5320.
94. Shahabi V., Reyes-Reyes M., Wallecha A., Rivera S., Paterson Y., Maciag P.C. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol. Immunother. 2008, 57:1301-1313.
95. Shahabi V., Seavey M.M., Maciag P.C., Rivera S., Wallecha A. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther. 2011, 8:53-62.
96. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2, its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006, 13:63-69.
97. + T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res. 2006, 66:7748-7757.
98. Singh R., Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 2007, 67:1887-1892.
99. Singh R., Dominiecki M.E., Jaffee E.M., Paterson Y. Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 2005, 175:3663-3673.
100. Souders N.C., Verch T., Paterson Y. In vivo bactofection, Listeria can function as a DNA-cancer vaccine. DNA Cell Biol. 2006, 25:142-151.
101. Souders N.C., Sewell D.A., Pan Z.K., Hussain S.F., Rodriguez A., Wallecha A., Paterson Y. Listeria-based vaccines can partially overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun. 2007, 7:2.
102. Spreng S., Gentschev I., Goebel W., Mollenkopf H., Eck M., Müller-Hermelink H.K., Schmausser B. Novel bacterial systems for the delivery of recombinant protein or DNA. FEMS Immunol. Med. Microbiol. 2000, 27:299-304.
103. Starks H., Bruhn K.W., Shen H., Barry R.A., Dubensky T.W., Brockstedt D., Hinrichs D.J., Higgins D.E., Miller J.F., Giedlin M., Bouwer H.G. Listeria monocytogenes as a vaccine vector, virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J. Immunol. 2004, 173:420-427.
104. Stritzker J., Pilgrim S., Szalay A.A., Goebel W. Prodrug converting enzyme gene delivery by L. monocytogenes. BMC Cancer 2008, 8:94.
105. Takahashi N., Kawanishi-Tabata R., Haba A., Tabata M., Haruta Y., Tsai H., Seon B.K. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin. Cancer Res. 2001, 7:524-532.
106. Tam M.A., Wick M.J. Differential expansion, activation and effector functions of conventional and plasmacytoid dendritic cells in mouse tissues transiently infected with Listeria monocytogenes. Cell. Microbiol. 2006, 8:1172-1187.
107. Tindle R.W. Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. 1996, 8:643-650.
108. Tindle R.W., Frazer I.H. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunization. Curr. Top. Microbiol. Immunol. 1994, 186:217-253.
109. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., Rowley D.A. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA 1990, 87:1486-1490.
110. Van den Eynde B., Hainaut P., Hérin M., Knuth A., Lemoine C., Weynants P., van der Bruggen P., Fauchet R., Boon T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer 1989, 44:634-640.
111. Velge P., Bottreau E., Kaeffer B., Pardon P. Cell immortalization enhances Listeria monocytogenes invasion. Med. Microbiol. Immunol. 1994, 183:145-158.
112. Verch T., Pan Z.K., Paterson Y. Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect. Immun. 2004, 72:6418-6425.
113. Wadsworth S., Goldfine H. Mobilization of proteinase C in macrophages induced by Listeria monocytogenes affects its internalization and escape from the phagosome. Infect. Immun. 2002, 70:4650-4660.
114. Wallecha A., Carroll K.D., Maciag P.C., Rivera S., Shahabi V., Paterson Y. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anti-cancer immunotherapeutics. Adv. Appl. Microbiol. 2009, 66:1-27.
115. Wallecha A., Maciag P.C., Rivera S., Paterson Y., Shahabi V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin. Vaccine Immunol. 2009, 16:96-103.
116. Wang J.M., Kumar S., Pye D., van Agthoven A.J., Krupinski J., Hunter R.D. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 1993, 54:363-370.
117. Weiskirch L.M., Paterson Y. Listeria monocytogenes, a potent vaccine vector for neoplastic and infectious disease. Immunol. Rev. 1997, 158:159-169.
118. Wolf S.F., Sieburth D., Sypek J. Interleukin 12, a key modulator of immune function. Stem Cells 1994, 12:154-168.
119. Wood L.M., Pan Z.K., Shahabi V., Paterson Y. Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy. Cancer Immunol. Immunother. 2010, 59:1049-1058.
120. Wood L.M., Pan Z.K., Guirnalda P., Tsai P., Seavey M.M., Paterson Y. Targeting tumor vasculature with novel listeria-based vaccines directed against CD105. Cancer Immunol. Immunother. 2011, 60:931-942.
121. Wood L.M., Seavey M.M., Pan Z.K., Paterson Y. Targeting the tumor-associated ubiquitin-like protein, ISG15, as a novel strategy for breast cancer treatment. Cancer Immunol. Immunother. 2011, In Press.
122. Yu Y.A., Shabahang S., Timiryasova T.M., Zhang Q., Beltz R., Gentschev I., Goebel W., Szalay A.A. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 2004, 22:313-320.